Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 11/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.73 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | APAF1 | O14727 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138868 | 0.88 | ESR1 (0.69) | ESR1ESR2APPHSD17B1HSD17B2 | |
| Raloxifene Core SCHEMBL2567321 | 0.85 | ESR1 (1.00) | ESR1ESR2APPHSD17B1HSD17B2 | |
| Raloxifene Core SCHEMBL29941293 | 0.85 | ESR1 (1.00) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL21735080 | 0.84 | ESR1 (0.63) | ESR1ESR2APPALDH1A1MAPT | |
| SCHEMBL3627201 | 0.83 | ESR1 (0.46) | ESR1ESR2APPIKBKBHDAC6 | |
| SCHEMBL3139631 | 0.82 | ESR1 (1.00) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL1179605 | 0.79 | ESR1 (0.62) | ESR1ESR2APPCA2HDAC3 | |
| SCHEMBL22245878 | 0.79 | ESR1 (0.56) | ESR1ESR2APPALDH1A1MAPT | |
| SCHEMBL20473171 | 0.79 | MAPT (0.46) | ESR1ESR2APPGLACA2 | |
| SCHEMBL13071222 | 0.79 | ESR1 (0.80) | ESR1ESR2APPHSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753387-B2 | Compounds for optically active devices | Johnson & Johnson Surgical Vision, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753387-B2 | Compounds for optically active devices | Johnson & Johnson Surgical Vision, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-3889135-B1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-08-02 | — | — | EP | disclosed |
| EP-3889135-A1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3583092-B1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2021-05-26 | — | — | EP | disclosed |
| US-11014900-B2 | Hydrophilic compounds for optically active devices | MERCK PATENT GMBH (DE) | 2021-05-25 | — | — | US | disclosed |
| US-11014901-B2 | Hydrophobic compounds for optically active devices | MERCK PATENT GMBH (DE) | 2021-05-25 | — | — | US | disclosed |
| EP-3583098-B9 | HYDROPHILIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2021-05-12 | — | — | EP | disclosed |
| EP-3583091-B1 | HYDROPHOBIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2020-11-04 | — | — | EP | disclosed |
| EP-3583098-B1 | HYDROPHILIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-20200231559-A1 | HYDROPHILIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2020-07-23 | — | — | US | disclosed |
| US-20200055833-A1 | HYDROPHOBIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2020-02-20 | — | — | US | disclosed |
| EP-2137193-B1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2017-08-09 | — | — | EP | disclosed |
| US-8642603-B2 | Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof | SANOFI (FR) | 2014-02-04 | — | — | US | disclosed |
| US-20100075994-A1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2010-03-25 | — | — | US | disclosed |
| EP-2137193-A2 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | Sanofi-Aventis (FR) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008112483-A2 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055833-A1 | HYDROPHOBIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | UACA, CRYZ, TRPA1 | ESR1 1822/4885ESR2 3189/4885APP 450/4885 |
| US-20100075994-A1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | GRM2, GRM1, GRIN2C | ESR1 699/4885ESR2 491/4885APP 662/4885 |
| US-11753387-B2 | Compounds for optically active devices | PDE6C, PDE6A, PDE6D | ESR1 1260/4885ESR2 3107/4885APP 899/4885 |
| US-11014901-B2 | Hydrophobic compounds for optically active devices | UACA, CRYZ, TRPA1 | ESR1 1822/4885ESR2 3189/4885APP 450/4885 |
| US-20200231559-A1 | HYDROPHILIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | AQP1, AQP3, AQP4 | ESR1 2055/4885ESR2 3888/4885APP 1043/4885 |
| US-11014900-B2 | Hydrophilic compounds for optically active devices | AQP1, AQP3, AQP4 | ESR1 2055/4885ESR2 3888/4885APP 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.